Document:

Exhibit 10.3

 

OMNIBUS AMENDMENT AND REAFFIRMATION AGREEMENT

 

(Loan from East Boston Savings Bank)

 

 

This Omnibus Amendment and Reaffirmation
Agreement (“Agreement”) is made as of the 23rd day of April, 2020, between and among Gano Holdings,
LLC, a Rhode Island limited liability company (“Borrower”), Procaccianti Hotel REIT, Inc. (“GPHREIT”),
a Maryland corporation, and East Boston Savings Bank (“Bank”).

 

WHEREAS, the Bank earlier
made a loan to Borrower in the original amount of Thirteen Million One Hundred Thirty-Five Thousand Dollars ($13,135,000.00), increased
in 2019 by Two Million Five Hundred Thousand Dollars ($2,500,000.00), and later increased in 2020 to $16,936,900.72, which loan
(as previously so increased, the “Existing Loan”) is secured in part by improved property located at 220 India
Street, Providence, Rhode Island, on which there is a 137-key hotel and parking area known as the Hilton Garden Inn (the “Hotel”),
and which Loan as most recently modified by the terms and provisions of the Loan Documents, as “Loan Documents” is
defined in paragraph 3 of the Omnibus Amendment, Assignment, Assumption, Release and Reaffirmation Agreement dated February 21,
2020 and as amended on March 24, 2020 between and among the Borrower, GPHREIT, the Bank and others (collectively, the “Prior
Omnibus Amendment”); and

 

WHEREAS, at Borrower’s request due
to the economic disruption caused by the COVID-19 virus, the Bank and Borrower have agreed to limited economic relief via a temporary
deferral of sums otherwise payable under the Note, and certain other changes to the Loan as hereinafter noted;

 

NOW THEREFORE, for good and valuable consideration
including the modifications to the Loan Documents hereinafter noted, the parties hereto agree as follows:

 

		1.	Capitalized terms used herein and not otherwise defined in this Agreement shall have the meanings ascribed to them according
to the terms of paragraph 3 of the prior Omnibus Agreement;

 

		2.	The provisions for payment of interest on the Note as set forth in subparagraph (a) on page 1 of the Note are modified with
respect to the six payments, only, otherwise due on the six (6) consecutive payment days starting with the Payment Day (i.e., the
15th) in April, 2020. With respect to each of those six payments, the date for payment will be deferred until the date
twelve (12) months after the date originally due (e.g., the payment originally due April 15, 2020 will be due one year thereafter,
on April 15, 2021),

 

		3.	(a)       All financial covenant testing and any requirements of the Borrower to comply with the same contained in the Loan Documents
are waived until the year ending December 31, 2021.

 

(b)       All
net worth, liquidity and financial covenant testing and any requirements of the Guarantor to comply with the same contained in
the Loan Documents are waived until the year ending December 31, 2021.

 

     

     

    

 

		4.	The Borrower hereby makes the following additional representations and warranties to the Bank:

 

a.                  
Beneficial Ownership Certificate: The Beneficial Ownership Certificate form (the “BOC”) submitted by the Borrower
in connection with this Agreement is an accurate representation as of the date hereof of all individuals who own at least twenty-five
percent (25%) of the ownership interests in the Borrower, and the name of the individual who is currently responsible for controlling,
managing or directing the Borrower.

 

b.                 
Prohibition of Certain Changes: Except as otherwise provided in the Loan Documents (including without limitation, the provisions
of Section 6.3 of the Mortgage), the Borrower will not without the prior written consent of the Bank which shall not be unreasonably
withheld or delayed: (i) change its name or enter into any merger or consolidation or effect any reorganization or recapitalization;
(ii) except as required by any governmental order or requirement, make or permit any substantial change in, or cease in whole or
in any material part, its business as now, or proposed to be, conducted; (iii) except as required by any governmental order or
requirement, engage in any other activities materially different from the business now conducted; (iv) make any changes in the
present executive or management personnel controlling the Borrower except for changes necessitated by the death or voluntary or
involuntary termination of employment of any management personnel controlling the Borrower; (v) transfer twenty-five percent (25%)
or more of the direct or indirect ownership interests in the Borrower; or (vi) subject to all of the foregoing, make any changes
in the ownership interests of the Borrower, such that there is a material change, as determined by the Bank in its reasonable discretion,
in the direct or indirect ownership interests of the Borrower.

 

c.                  
Notification of Changes in the Borrower: The Borrower shall notify the Bank in writing sixty (60) days prior to: (i) any
change in the direct or indirect ownership interests in the Borrower, unless no notice of such changes are required by the Loan
Documents prior to this amendment and the change would not cause the last-delivered BOC to be inaccurate; or (ii) any change in
the executive or management personnel controlling the Borrower.  Written notice of any such proposed change shall be accompanied
by a new Beneficial Ownership Certificate on the Bank’s form, which includes any updates or changes to the current form on
file with the Bank.

 

     

     

    

 

		5.	From and after the Payment Day for April 2020, through and including the date on which the Borrower repays to the Bank all
deferred interest, the Borrower and Guarantor will provide the Bank with such financial information as the Bank may reasonably
request in writing.

 

		6.	Notwithstanding anything in the Loan Documents to the contrary, Bank agrees that Borrower or its affiliates may apply for and
obtain a so-called Paycheck Protection Program loan from the United States Small Business Administration (or any United States
Small Business Administration approved lender) for the Hotel in such amounts as approved by such lenders and such loan shall is
and shall hereby be allowed by Bank (without the requirement of any further consent, notice or approval by Bank ).

 

		7.	Notwithstanding anything in the Loan Documents to the contrary, Bank agrees that Borrower has satisfied any requirement in
the Loan Documents to provide any notices to Bank (and further, the Bank waives any requirements of any notice by Borrower) with
respect to the existence of this novel coronavirus (COVID-19) pandemic.

 

		8.	On or before the date of full execution and delivery of this Agreement, and thereafter unless and until the Loan is fully repaid,
the Borrower will maintain its operating account for the Property with the Bank.

 

		9.	Each of the Borrower and Guarantor certify to the Bank that the party signing and delivering this document on its behalf has
full power and authority to do so, that such person has signed and delivered the Agreement, and that the respective obligations
of Borrower and Guarantor contained herein are enforceable in accordance with their terms.

 

		10.	Except only to the extent modified by the terms set forth in this Agreement, all the terms and provisions of the Loan Documents
are hereby ratified and confirmed, and remain in full force and effect, respectively enforceable against Borrower and Guarantor,
as applicable, without claim of any default for non-performance or otherwise through the date hereof against the Bank.

 

		11.	Given the restrictions imposed as a result of COVID-19, the Borrower and the Bank acknowledge and agree that delivery of an
executed counterpart of this Amendment by facsimile, email transmission of a scanned image, or other electronic means shall be
effective as delivery of an originally executed counterpart. Borrower, Guarantor and Bank agree that “execution,” “signed,”
 “signature,” and words of like import in this document shall be deemed to include electronic signatures or the keeping
of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed
signature or the use of a paper-based record keeping system, as the case may be, to the extent and as provided for in any applicable
law, including, without limitation, The Massachusetts Uniform Electronic Transactions Act, the Electronic Signatures in Global
and National Commerce Act, the Uniform Electronic Transactions Act or the Uniform Commercial Code, and the parties hereto hereby
waive any objection to the contrary.

 

 

[END OF TEXT; SIGNATURES ON NEXT PAGES]

 

     

     

    

 

Executed under seal as of the date first above written.

 

	BORROWER:	 
	 	 	 
	GANO HOLDINGS, LLC,	 
	a Rhode Island limited liability company	 
	 	 	 
	By: 	/s/ James A. Procaccianti	
	 	James A. Procaccianti, 	 
	 	Its Authorized Signatory	 
	 	 	 
	 	 	 
	GPHREIT:	 
	 	 	 
	Procaccianti Hotel REIT, INC.,	 
	a Maryland corporation	 
	 	 	 
	By: 	/s/ James A. Procaccianti	
	 	James A. Procaccianti, 	 
	 	Its Authorized Signatory	 

 

     

     

    

 

STATE OF RHODE ISLAND

 

On the 21st day of April, 2020 before me, the undersigned
notary public, personally appeared James A. Procaccianti, personally known to the notary to be the person whose name is signed
on the preceding or attached document, and acknowledged to the notary that he signed it voluntarily for its stated purpose.

 

	 	/s/ Ron M. Hadar	 
	 	NOTARY PUBLIC
	[Affix Notarial Seal]	 	 	 
	 	Printed Name:	 Ron M. Hadar	 
	 	My Commission Expires:	 12/28/2023	 

 

 

	BANK:	 
	 	 	 
	EAST BOSTON SAVINGS BANK	 
	 	 	 
	 	 	 
	By:	/s/ Jonpaul Sallese	
	 	Jonpaul Sallese	 
	 	Vice President, Commercial Real EstateExhibit 10.1 

EXECUTIVE EMPLOYMENT AGREEMENT

This EXECUTIVE EMPLOYMENT
AGREEMENT (this “Agreement”) is made as of April 17, 2020 (the “Effective Date”)
by and between CorMedix Inc., a Delaware corporation (the “Company”), and John L. Armstrong, Jr. (“Executive”).
Each of the Company and Executive is referred to herein as a “Party” and together they are referred to
as the “Parties.”

TERMS

In consideration
of the foregoing premises and the mutual covenants and agreements herein contained, the Parties, intending to be legally bound,
agree as follows:

1.                 
Employment.

(a)               
Agreement. The Parties are subject to an Employment Agreement dated as of March 1, 2017 (the “2017 Employment
Agreement”). The Parties wish to enter into this Agreement, which shall replace and supersede the 2017 Employment
Agreement, effective as of the Effective Date.

(b)              
Services. Executive will continue to serve as the Company’s Executive Vice President, Technical Operations.
Executive will report directly to, and be subject to the supervision of, the Company’s Chief Executive Officer (the “CEO”).
Executive will perform such services for the Company and have such powers, responsibilities and authority as are customarily associated
with the position of Executive Vice President, Technical Operations and shall perform customary and appropriate duties as may otherwise
be reasonably assigned to the Executive from time to time by the CEO.

(c)               
Acceptance. Executive hereby accepts such employment subject to the terms of this Agreement.

2.                 
Term.

The duration of
employment under this Agreement shall commence on the Effective Date and shall continue for a term of three (3) years thereafter,
unless sooner terminated pursuant to Section 8 (such three-year period referred to herein as the “Initial
Term”); provided, however, that on the expiration
of the Term, the Term shall be extended automatically for additional, successive one-year periods (such extended periods referred
to herein as the “Extended Term”), unless one Party shall notify the other in writing at least ninety
(90) days before the initial expiration of the Initial Term or the expiration of any successive one-year period during the Extended
Term that this Agreement shall not be so extended after such expiry (a “Notice of Nonrenewal”). The Initial
Term and the Extended Term collectively shall be referred to herein as the “Term.” Notwithstanding anything
to the contrary contained herein, the provisions of this Agreement specified in Sections 5, 6, 9, 10, 11, 12, and 13
shall survive the expiration or termination hereof.

3.                 
Duties; Place of Performance.

(a)               
Duties. Except as otherwise set forth in this Section 3(a), Executive (i) shall devote all of his business time,
attention and energies to the business and affairs of the Company, shall use his best efforts to advance the interests of the Company,
and shall perform his duties diligently and to the best of his ability, in compliance with the Company’s policies and procedures
and the laws and regulations that apply to the Company’s business;
and (ii) shall not be engaged in any other business activity, whether or not such business activity is pursued for gain,
profit or other pecuniary advantage, that will interfere with the performance by Executive of his duties hereunder or Executive’s
availability to perform such duties or that Executive knows, or should reasonably know, will adversely affect, or negatively reflect
upon, the Company. With the advance written consent of the Company’s Board of Directors (the “Board”),
Executive may serve as a director of, or on the advisory committee of, other pharmaceutical and life science companies.

    -1- 

     

    

(b)              
Place of Performance. The duties to be performed by Executive hereunder shall be performed remotely, subject to reasonable
travel requirements on behalf of the Company, and provided that the Company can require Executive to work at the Company’s
headquarters for a reasonable number of days per month.

4.                 
Compensation.

As full compensation
for Executive’s performance of services as an employee of the Company, the Company shall pay Executive as follows:

(a)               
Base Salary. During the Initial Term, the Company shall pay Executive an annual base salary of three hundred twenty
five thousand dollars ($325,000) (as it may be increased from time to time as provided hereunder, the “Base Salary”),
less applicable withholdings and deductions. Payment shall be made in accordance with the Company’s normal payroll practices.
Upon the expiration of the Initial Term, the Board, or its Compensation Committee, shall review the Base Salary to determine whether
an increase in the amount thereof is warranted in its sole discretion. The Base Salary will not be decreased unless (i) all officers
and/or members of the Company’s executive management team experience an equal or greater percentage reduction in annual base
salary and/or total compensation; and (ii) Executive’s Base Salary reduction is no greater than twenty-five percent
(25%).

(b)              
Annual Bonus. Subject to the following provisions of this Section 4(b), Executive shall be eligible
for an annual bonus, less applicable withholdings and deductions, based upon a target amount of thirty five percent (35%) of the
Base Salary then in effect, as determined by the Board (or its Compensation Committee) in good faith based upon the achievement,
during the year in question, of corporate objectives for the Company as a whole established by the Board (or its Compensation Committee)
and such other factors as the Board (or its Compensation Committee) deems appropriate. Executive must be employed by the Company
through December 31 of a given year in order to be eligible to earn the annual bonus for such year. The annual bonus for a given
year will be paid no later than March 15 of the year following the year to which it relates.

(c)               
Equity Grants. Each year during the Term, the Board (or its Compensation Committee) will make an annual equity grant
to Executive, which may include restricted stock or restricted stock units (“Awards”) or options to purchase
shares of capital stock of the Company (“Stock Options”), with time-based or performance-based vesting,
in such amounts and on such terms as the Board (or its Compensation Committee) deems appropriate.

(d)              
Withholding. The Company will withhold from any amounts payable under this Agreement such federal, state and local
taxes as the Company determines are required to be withheld pursuant to applicable law.

(e)               
 Expenses. The Company shall reimburse Executive for all normal, usual and necessary expenses incurred by Executive
in furtherance of the business and affairs of the Company, including without limitation reasonable travel, lodging, meals, and
entertainment, upon timely receipt by the Company of appropriate vouchers or other proof of Executive’s expenditures and
otherwise in accordance with any expense reimbursement policy as may from time to time be adopted by the Company. Such reimbursements
will be made in a timely manner and in accordance with the policies of the Company, but in no event later than December 31 of the
year following the year in which Executive incurs such expense. The amount of expenses eligible for reimbursement during one year
will not affect the expenses eligible for reimbursement in any other year, and is not subject to liquidation or exchange for another
benefit.

(f)               
Other Benefits. Executive shall be entitled to all rights and benefits for which he shall be eligible under any benefit
or other plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee
stock purchase plans, profit sharing plans, bonus plans, prescription drug reimbursement plans, short and long term disability
plans, life insurance and other so-called “fringe” benefits) as the Company shall make available to its senior executives
from time to time. All such benefits are subject to the provisions of their respective plan documents in accordance with their
terms and are subject to amendment or termination by the Company without Executive’ s consent.

(g)               
Vacation. Executive shall be entitled to a vacation up to thirty (30) days per annum, of which no more than two (2)
weeks may be taken consecutively, in addition to holidays observed by the Company and reasonable periods of paid personal and sick
leave. All such paid time off shall accrue and be used in accordance with the Company’s established policies and procedures.

    -2- 

     

    

5.                 
Confidential Information and Inventions.

(a)               
Confidential Information; Non-Disclosure and Non-Use. Executive recognizes and acknowledges that in the course
of his duties he will receive confidential or proprietary information of the Company, its affiliates or third parties with whom
the Company or any such affiliates has an obligation of confidentiality. Accordingly, during and after the Term, Executive agrees
to keep confidential and not disclose or make accessible to any other person or use for any other purpose other than in connection
with the fulfillment of his duties under this Agreement, any “Confidential and Proprietary Information” (defined below)
owned by, or received by or on behalf of the Company or any of its affiliates. The term “Confidential and Proprietary
Information” shall include, but shall not be limited to, confidential or proprietary scientific or technical information,
data, formulas and related concepts, business plans (both current and under development), client lists, promotion and marketing
programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs,
revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, financing methods,
and any and all information relating to the operation of the Company’s business which the Company may from time to time designate
as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by the Company as confidential
or proprietary. Executive expressly acknowledges that the Confidential and Proprietary Information constitutes a protectable business
interest of the Company. Confidential and Proprietary Information encompasses all formats in which information is preserved, whether
electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof. Executive
agrees: (i) not to use any such Confidential and Proprietary Information for himself or others; and (ii) not to take any Company
material or reproductions (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and
business policies, computer programs or disks) thereof from the Company’s offices at any time during his employment by the
Company, except in connection with the execution of Executive’s duties to the Company.

(b)              
Return of Property. Upon request during employment and immediately at the termination of his employment, Executive
will return to the Company all Confidential and Proprietary Information in any form (including all copies and reproductions thereof)
and all other property whatsoever of the Company in his possession or under his control. If requested by the Company, Executive
will certify in writing that all such materials have been returned to the Company. Executive also expressly agrees that immediately
upon the termination of his employment with the Company for any reason, Executive will cease using any secure website, computer
systems, e-mail system, phone system or voicemail service provided by the Company for the use of its employees. Notwithstanding
the foregoing, Executive may retain his address book to the extent it only contains contact information.

(c)               
Exceptions. Confidential and Proprietary Information does not include any information that: (i) at the time of disclosure
is generally known to, or readily ascertainable by, the public; (ii)
becomes known to the public through no fault of Executive or other violation of this Agreement;
or (iii) is disclosed to Executive by a third party under no obligation to Executive’s knowledge to maintain the confidentiality
of the information. The restrictions in Section 5(a) above will not apply to any information the extent that that
Executive is required to disclose such information by law, provided that the Executive (x) notifies the Company of the existence
and terms of such obligation, (y) gives the Company prompt notice to seek a protective or similar order to prevent or limit such
disclosure, and (z) only discloses that information actually required to be disclosed. Notwithstanding the foregoing, nothing in
this Agreement is meant to prohibit Executive from reporting possible violations of federal law or regulation to any governmental
agency or entity, including but not limited to the Department of Justice, the SEC, the Congress, and any agency Inspector General,
or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. Executive shall
not be required to obtain the prior authorization of the Company to make any such reports or disclosures and is not required to
notify the Company that he has made such reports or disclosures.

(d)              
Notice Of Immunity From Liability For Confidential Disclosure Of A Trade Secret To The Government Or In A Court Filing.
Pursuant to the Federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state or local
government official, either directly or indirectly, or to an attorney;
and (ii) solely for the purpose of reporting or investigating a suspected violation of law;
or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade
secret to his attorney and use the trade secret information in the court proceeding, if the individual (a) files any document containing
the trade secret under seal; and (b) does not disclose the trade
secret, except pursuant to court order.

    -3- 

     

    

(e)               
Inventions. Executive agrees that all inventions, discoveries, improvements and patentable or copyrightable works
(“Inventions”) initiated, conceived or made by him within the scope of the Company’s business and
in the course of his employment with the Company, either alone or in conjunction with others, during the Term shall be the sole
property of the Company to the maximum extent permitted by applicable law and, to the extent permitted by law, shall be “works
made for hire” as that term is defined in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be
the sole owner of all patents, copyrights, trade secret rights, and other intellectual property or other rights in connection therewith;
provided, however that this Section 5(e) shall not apply to Inventions which are not related to the business
of the Company and which are made and conceived by Executive not during normal working hours, not on the Company’s premises
and not using the Company’s tools, devices, equipment or Confidential and Proprietary Information. Subject to the foregoing,
Executive hereby assigns to the Company all right, title and interest he may have or acquire in all Inventions;
provided, however, that the Board may in its sole discretion agree to waive the Company’s rights pursuant to this
Section 5(e).

(f)               
Further Actions and Assistance. Executive agrees to cooperate reasonably with the Company and at the Company’s
expense, both during and after his employment with the Company, with respect to the procurement, maintenance and enforcement of
copyrights, patents, trademarks and other intellectual property rights (both in the United States and foreign countries) relating
to the Inventions. Executive shall sign all papers, including, without limitation, copyright applications, patent applications,
declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, that the Company reasonably may
deem necessary or desirable in order to protect its rights and interests in any Inventions. Executive further agrees that if the
Company is unable, after reasonable effort, to secure Executive’s signature on any such papers, any officer of the Company
shall be entitled to execute such papers as his agent and attorney-in-fact and Executive hereby irrevocably designates and appoints
each officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf and to take any and all
actions as the Company reasonably may deem necessary or desirable in order to protect its rights and interests in any Inventions,
under the conditions described in this Section 5(f).

(g)               
Prior Inventions. Executive will not assert any rights to any invention, discovery, idea or improvement relating
to the business of the Company or to his duties hereunder as having been made or acquired by Executive prior to his work for the
Company, except for the matters, if any, described in Exhibit A to this Agreement.

(h)              
Disclosure. Executive agrees that he will promptly disclose to the Company all Inventions initiated, made, conceived
or reduced to practice by him, either alone or jointly with others, during the Term.

(i)                
Survival. The provisions of this Section 5 shall survive any termination of this Agreement.

6.                 
Non-Competition, Non-Solicitation and Non-Disparagement.

(a)               
Executive understands and recognizes that his services to the Company are special and unique and that in the course of performing
such services Executive will have access to and knowledge of Confidential and Proprietary Information. Executive agrees that, during
the Term and the twelve (12) month period immediately following Executive’s separation from employment (the “Termination
Restriction Period”), whether such separation is voluntary or involuntary, he shall not in any manner, directly or
indirectly, on behalf of himself or any person, firm, partnership, joint venture, corporation or other business entity (“Person”),
enter into or engage in any business involving the development or commercialization of a preventive anti-infective product that
would be a competitor of Neutrolin or a product containing taurolodine or any other product being actively developed or produced
by the Company as of the date of Executive’s termination of employment (the “Business of Company”),
either as an individual for his own account, or as a partner, joint venturer, owner, executive, employee, independent contractor,
principal, agent, consultant, salesperson, officer, director or shareholder of such Person, in any capacity that requires or could
result in Executive’s intentional or unintentional use of the Confidential and Proprietary Information and/or requires Executive
to perform services substantially similar to those performed for the benefit of the Company during the Term, anywhere in the world,
provided, however, that nothing shall prohibit Executive from performing executive duties for any Person that does not engage in
the Business of Company. Executive acknowledges that, due to the unique nature of the Business of the Company, the Company has
a strong legitimate business interest in protecting the continuity of its business interests and its Confidential and Proprietary
Information and the restriction herein agreed to by Executive narrowly and fairly serves such an important and critical business
interest of the Company. Notwithstanding the foregoing, nothing contained in this Section 6(a) shall be deemed to
prohibit Executive from acquiring or holding, solely for investment, publicly traded securities of any corporation, some or all
of the activities of which are engaged in the Business of Company so long as such securities do not, in the aggregate, constitute
more than four percent (4%) of any class or series of outstanding securities of such corporation;
or being a passive investor holding less than four percent (4%) of a private equity, venture capital or other commingled
fund; and further notwithstanding the foregoing, nothing contained
in this Section 6(a) shall preclude Executive from becoming an employee of, or from otherwise providing services
to, a separate division or operating unit of a multi-divisional business or enterprise (a “Division”)
if: (i) the Division by which Executive is employed, or to which Executive provides services, is not engaged in the Business of
Company, (ii) Executive does not provide services, directly or indirectly, to any other division or operating unit of such multi-divisional
business or enterprise engaged in or proposing to engage in the Business of Company (individually, a “Competitive Division”
and collectively, the “Competitive Divisions”) and (iii) the Competitive Divisions, in the aggregate,
accounted for less than one-third of the multi-divisional business or enterprise’s consolidated revenues for the fiscal year,
and each subsequent quarterly period, prior to Executive’s commencement of employment with or provision of services to the
Division.

    -4- 

     

    

(b)              
Reasonableness of Restriction. Executive hereby acknowledges and agrees that the covenant against competition provided
for pursuant to Section 6(a) is reasonable with respect to its duration, geographic area and scope. In addition,
Executive acknowledges that the Company engages in the Business of Company throughout the world, and Executive has been involved
in the Business of the Company in that geographic area. If, at the time of enforcement of this Section 6, a court
holds that the restrictions stated herein are unreasonable under the circumstances then existing, the Parties hereto agree that
the maximum duration, scope or geographic area legally permissible under such circumstances will be substituted for the duration,
scope or area stated herein.

(c)               
Non-Solicitation. During the Term and the applicable Termination Restriction Period (as defined below), Executive
shall not, directly or indirectly, on his own behalf or on behalf of any person or entity, without the prior written consent of
the Company:

(i)                
solicit or induce any employee, consultant or independent contractor of the Company or any of its affiliates to leave the
employ of (or end a contracting relationship with) the Company or any affiliate;
or hire for any competitive purpose any employee consultant or independent contractor of the Company;
or hire any former employee who has left the employment of the Company or any affiliate of the Company within six (6) months
of the termination of such employee’s employment with the Company or any such affiliate for any competitive purpose;
or hire any former consultant or independent contractor who has ended his or her consultancy or contracting relationship
with the Company or any affiliate of the Company within six (6) months of the end of such consultancy or contracting relationship
for any competitive purpose; or hire any former employee of the
Company in knowing violation of such employee’s non-competition agreement with the Company or any such affiliate;
or

(ii)              
solicit, divert or take away, or attempt to divert or take away, the business or patronage of any agent, client or customer
of the Company which was served by the Company during the twelve (12) -month period prior to the termination of Executive’s
employment with the Company; or induce, encourage, or attempt to
induce or encourage any client or customer of the Company which was served by the Company during the twelve (12) -month period
prior to the termination of Executive’s employment with the Company to reduce, limit, or cancel its business with the Company.

For clarity, the foregoing shall not
be violated by general advertising, by serving as a reference upon request or by actions taken in the good faith performance of
Executive’s duties to the Company.

(d)              
Non-Disparagement. Executive agrees that he shall not directly or indirectly disparage, whether or not truthfully,
the name or reputation of the Company or any of its affiliates, including but not limited to, any officer, director, employee or
shareholder (provided Executive has had material dealings with such shareholder) of the Company or any of its affiliates;
provided that, nothing in this Section shall be construed to interfere with Executive’s right to engage in protected
concerted activity under the National Labor Relations Act. Notwithstanding this Section 6(d), nothing contained herein
shall apply to statements made by Executive (x) in the course of his responsibility to evaluate the performance and/or participate
in any investigation of the conduct or behavior of officers, employees and/or others, (y) as part of any judicial, administrative
or other legal action or proceeding, or (z) in rebuttal of false or misleading statements by others, and nothing shall be construed
to limit or impair the ability of Executive to provide truthful testimony in response to any validly issued subpoena or to file
pleadings or respond to inquiries or legal proceedings by any government agency to the extent required by applicable law. These
non-disparagement obligations will cease to apply two (2) years after Executive’s termination of employment.

(e)               
Enforcement. In the event that Executive breaches or threatens to breach any provisions of Section 5
or this Section 6, then, in addition to any other rights the Company may have, it shall be entitled to seek injunctive
relief to enforce such provisions. In the event that an actual proceeding is brought in equity to enforce the provisions of Section
5 or this Section 6, Executive shall not urge as a defense that there is an adequate remedy at law nor shall
the Company be prevented from seeking any other remedies that may be available to it nor shall the Company be required to post
a bond.

    -5- 

     

    

(f)               
Remedies Cumulative; Judicial Modification. Each of the rights and remedies enumerated in Section 6(e)
shall be independent of the others and shall be in addition to and not in lieu of any other rights and remedies available to the
Company at law or in equity. If any of the covenants contained in this Section 6, or any part of any of them, is
hereafter construed or adjudicated to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants
or rights or remedies, which shall be given full effect without regard to the invalid portions. If any of the covenants contained
in this Section 6 is held to be invalid or unenforceable because of the duration of such provision or the area covered
thereby, the Parties agree that the court making such determination shall have the power to reduce the duration and/or area of
such provision and in its reduced form such provision shall then be enforceable.

(g)               
Survival. The provisions of this Section 6 shall survive any termination of this Agreement.

7.                 
Representations and Warranties.

(a)               
By Executive. Executive hereby represents and warrants to the Company as follows:

(i)                
Neither the execution or delivery of this Agreement nor the performance by Executive of his duties and other obligations
hereunder conflict with or constitute a default or breach of any covenant or obligation under (whether immediately, upon the giving
of notice or lapse of time or both) any prior employment agreement, contract, or other instrument to which Executive is a party
or by which he is bound.

(ii)              
Executive has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and
other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of Executive enforceable against
him in accordance with its terms. No approvals or consents of any persons or entities are required for Executive to execute and
deliver this Agreement or perform his duties and other obligations hereunder.

(iii)            
Executive will not use any confidential information or trade secrets of any third Party in his employment by the Company
in violation of the terms of the agreements under which he had access to or knowledge of such confidential information or trade
secrets.

(b)              
By The Company. The Company hereby represents and warrants to Executive that the Company has the full right and power
to enter and deliver this Agreement and to perform its obligations hereunder. This Agreement constitutes the legal, valid and binding
obligation of the Company enforceable against it in accordance with its terms. All approvals or consents required for the Company
to validly execute and deliver this Agreement and perform its obligations hereunder, including, without limitation, approval of
the Board, if required, have been obtained.

8.                 
Termination.

(a)               
Cause. Executive’s employment hereunder may be terminated by the Company immediately for Cause. Any of the
following actions by Executive shall constitute “Cause”:

(i)                
The willful failure, disregard or refusal by Executive to perform his material duties or obligations under this Agreement
(other than as a result of Executive’s mental incapacity or illness, as confirmed by medical evidence provided by a physician
selected by the Company);

    -6- 

     

    

(ii)              
Any willful, intentional or grossly negligent act by Executive having the effect of materially injuring (whether financially
or otherwise) the business or reputation of the Company or any of its affiliates (other than acts that were performed in a good
faith attempt to advance the business interests of the Company);

(iii)            
Executive’s conviction of any felony involving moral turpitude (including entry of a guilty or nolo contendere plea);

(iv)            
The Executive’s qualification as a “bad actor,” as defined by 17 CFR 230.506(a);

(v)              
The good faith determination by the Board, after a reasonable and good-faith investigation by the Company that Executive
engaged in some form of harassment prohibited by law (including, without limitation, harassment on the basis of age, sex or race)
unless Executive’s actions were specifically directed by the Board;

(vi)            
Any material misappropriation or embezzlement by Executive of the property of the Company or its affiliates (whether or
not a misdemeanor or felony); or

(vii)          
Breach by Executive of any material provision of this Agreement that is materially injurious to the Company.

Notwithstanding the
foregoing, in no event shall Cause exist unless the Company’s Board has made a formal determination of Cause by majority
vote and provided Executive with ten (10) days advance notice followed by the right to be heard in front of the entire Board followed
by a second majority vote finding that Cause still exists. Such meeting of the Board can occur in person or via teleconference.
If the circumstances surrounding Cause are reasonably curable, then the Executive shall have the right to cure those circumstances
over the next twenty (20) days. If the circumstances are not curable or if those circumstances still exist after the cure period
has expired, then (and only then) shall Cause be deemed to exist for purposes of this Agreement.

(b)              
Death. Executive’s employment hereunder shall be terminated upon Executive’s death.

(c)               
Disability. The Company may terminate Executive’s employment hereunder due to Executive’s “Disability”
(defined below) while Executive is so Disabled. For purposes of this Agreement, a termination due to Executive’s “Disability”
shall be deemed to have occurred if the Executive has not been able to perform his material duties for one hundred eighty (180)
days in a three hundred sixty five (365) day period.

(d)              
Good Reason. Executive may terminate his employment hereunder for “Good Reason” (as defined below) pursuant
to the procedures set forth in this Section 8(d). In order for Executive to resign for Good Reason, Executive must
provide written notice to the Board of the existence of the Good Reason condition within sixty (60) days of the initial existence
of such Good Reason condition. Upon receipt of such notice, the Company will have thirty (30) days during which it may attempt
to remedy the Good Reason condition. If so remedied, Executive may not resign for Good Reason based on such condition. If the Good
Reason condition is not remedied within such thirty (30) day period, Executive may resign based on the Good Reason condition specified
in the notice effective no later than thirty (30) days following the expiration of the thirty (30) day cure period. The term “Good
Reason” shall mean any of the following occurring without the Executive’s consent:

(i)                
any material breach of this Agreement by the Company;

(ii)              
any material reduction by the Company of Executive’s duties, responsibilities, or authority;

(iii)            
a material reduction in Executive’s annual Base Salary unless (i) all officers and/or members of the Company’s
executive management team experience an equal or greater percentage reduction in annual base salary and/or total compensation;
and (ii) Executive’s Base Salary and/or total compensation reduction is no greater than twenty-five (25) percent;
or

    -7- 

     

    

(iv)            
a material reduction in Executive’s target bonus level unless: (i) all officers and/or members of the Company’s
executive management team experience an equal or greater percentage reduction related to target bonus levels;
and (ii) Executive’s target bonus level reduction is no greater than twenty-five (25) percent.

(e)               
Convenience. Either Party may terminate Executive’s employment hereunder for any reason or no reason at any
time upon sixty (60) days written notice of termination to the other Party, which notice shall specify the termination date, or
by providing a Notice of Nonrenewal to the other Party pursuant to the terms of Section 2.

9.                 
Compensation upon Termination.

In the event Executive’s
employment is terminated, the Company shall pay to Executive the Base Salary and benefits otherwise payable to him under Section
4 through the last day of his actual employment by the Company, along with any reimbursable business expenses subject to
Company policy and any amounts due under any benefit plan or program in accordance with its terms (together, the “Accrued
Compensation”). Except for the Accrued Compensation, rights to indemnification and directors’ and officers’
liability insurance, and as otherwise required by law, Executive will have no further entitlement hereunder to any other compensation
or benefits from the Company except as expressly provided below:

(a)               
Death or Disability. If Executive’s employment is terminated as a result of his death or Disability, the Company
shall pay to Executive or to Executive’s estate, as applicable, the Accrued Compensation. In addition, Executive shall receive
the bonus due for any completed fiscal year to the extent that such bonus has not yet been paid (including timing of payment, the
“Prior Year Bonus”).

(b)              
Cause. If Executive’s employment is terminated by the Company for Cause, Executive shall not be entitled to
receive any payments or benefits other than the Accrued Compensation, rights to indemnification and directors’ and officers’
liability insurance and as otherwise required by law. All outstanding Awards and Options that were granted to Executive by the
Company before the Effective Date that have not vested as of the date of termination shall be forfeited as of that date. All outstanding
Awards and Options that are granted on or after the Effective Date, whether or not vested, shall be forfeited to the Company as
of such date.

(c)               
Other than for Cause, Non-Renewal, Death or Disability. If the Company terminates Executive’s employment, other
than as a result of Executive’s death or Disability, other than by Notice of Nonrenewal and other than for Cause, or if Executive
terminates Executive’s employment for Good Reason, then conditioned upon Executive executing and not revoking a Release (as
defined below) following such termination, the Company will provide to Executive the following separation benefits:

(i)                
Payment of the Accrued Compensation and Prior Year Bonus, rights to indemnification and directors’ and officers’
liability insurance and any rights or privilege otherwise required by law,

(ii)              
Payment to Executive of an amount equal to nine (9) months of his Base Salary, which shall be paid over a period of nine
(9) months following the termination date,

(iii)            
Payment to Executive of a prorated annual bonus for the year in which the termination date occurs, based on the actual achievement
of the objectives referenced in Section 4(b). The prorated bonus will be calculated as the annual bonus based on
performance, multiplied by a fraction, the numerator of which is the number of days preceding the termination date in the year
of termination and the denominator of which is three hundred sixty five (365) (the “Prorated Bonus”).

(iv)            
If Executive timely elects continued health insurance coverage under COBRA, payment to Executive monthly of a portion of
the premium necessary to continue such coverage for Executive and Executive’s eligible dependents that is equal to the portion
paid for by the Company at the date of termination, until the conclusion of the time when Executive is receiving continuation of
Base Salary payments under Section 9(c)(ii) above or until Executive becomes eligible for group health insurance
coverage under another employer’s plan, whichever occurs first, provided however that the Company has the right to terminate
such payment of COBRA premiums on behalf of Executive and instead pay Executive a lump sum amount equal to the COBRA premium amount
described above times the number of months remaining in the specified period if the Company determines in its discretion that continued
payment of the COBRA premiums is or may be discriminatory under Section 105(h) of the Code, consistent with Section 409A of the
Code, and

    -8- 

     

    

(v)              
All Awards and Stock Options that are scheduled to vest on or before the next succeeding anniversary of the date of termination
shall be accelerated and deemed to have vested as of the termination date; provided that, for the avoidance of doubt, any performance-based
Awards and Stock Options whose vesting requirements have not been successfully met as of the date of Employee’s termination
of employment or resignation with Good Reason will not accelerate.. All Stock Options that have vested (or been deemed pursuant
to the immediately preceding sentence to have vested) as of the date of Executive’s termination shall remain exercisable
until the earlier of the expiry of ninety (90) days following such termination or the termination date applicable under the grant.

The separation benefits
set forth above are conditioned upon Executive executing a release of claims against the Company, its parents, subsidiaries and
affiliates and each of its officers, directors, employees, agents, successors and assigns in substantially the form attached hereto
as Exhibit B (the “Release”) within the time specified therein, which Release is not revoked within
any time period allowed for revocation under applicable law. The salary continuation described in Section 9(c)(ii)
above will be payable to Executive over time in accordance with the Company’s payroll practices and procedures beginning
on the sixtieth (60th) day following the termination of Executive’s employment with the Company, provided that the Company,
in its sole discretion but in accordance with Internal Revenue Code Section 409A, may begin the payments earlier. The Prorated
Bonus described in Section 9(c)(iii) above shall be paid at the date on which the annual bonus would have been paid
had Executive continued in employment, and the COBRA payments Section 9(c)(iv) above shall be paid monthly beginning
on the date on which the salary continuation commences.

(d)              
By Notice of Non-Renewal; Termination without Good Reason. If, pursuant to Section 8(e), Executive
terminates his employment hereunder by written notice of termination without Good Reason or if either Party terminates Executive’s
employment by providing a Notice of Nonrenewal to the other Party, Executive shall not be entitled to receive any payments or benefits
other than the Accrued Compensation, the Prior Year’s Bonus, rights to indemnification and directors’ and officers’
liability insurance and as otherwise required by law.

(e)               
This Section 9 sets forth the only obligations of the Company with respect to the termination of Executive’s
employment with the Company, and Executive acknowledges that, upon the termination of his employment, he shall not be entitled
to any payments or benefits which are not explicitly provided in this Section 9, except as required by law or the
terms of another employee plan, program or arrangement covering him. Executive acknowledges and agrees that upon the termination
of his employment with the Company, regardless of the reason or grounds therefor, he shall resign from any board, organization
or foundation wherein Executive sits or belongs as a representative of the Company.

(f)               
The obligations of the Company that arise under this Section 9 shall survive the expiration or earlier termination
of this Agreement.

10.             
Corporate Transaction.

(a)               
Corporate Transaction Defined. The term “Corporate Transaction” shall have the same meaning
as defined in the Company’s 2019 Omnibus Stock Incentive Plan, as in effect on the date of this Agreement.

(b)              
Consequence upon Executive’s Termination Without Cause or Executive’s Resignation With Good Reason. Upon
Executive’s termination of employment without Cause or Executive’s resignation of employment with Good Reason within
twenty-four (24) months after a Corporate Transaction, the Company shall provide Executive the following separation benefits:

(i)                
Payment of the Accrued Compensation, the Prior Year Bonus, rights to indemnification and directors’ and officers’
liability insurance and any rights or privilege otherwise required by law,

(ii)              
Payment to Executive of an amount equal to nine (9) months of his Base Salary and full target bonus as in effect for the
year of termination, which shall be paid over a period of nine (9) months following the termination date,

    -9- 

     

    

(iii)            
 Payment to Executive of the Prorated Bonus,

(iv)            
If Executive timely elects continued health insurance coverage under COBRA, payment to Executive monthly of a portion of
the premium necessary to continue such coverage for Executive and Executive’s eligible dependents that is equal to the portion
paid for by the Company at the date of termination, until the conclusion of the time when Executive is receiving continuation of
Base Salary and bonus payments under Section 9(c)(ii) above or until Executive becomes eligible for group health
insurance coverage under another employer’s plan, whichever occurs first, provided however that the Company has the right
to terminate such payment of COBRA premiums on behalf of Executive and instead pay Executive a lump sum amount equal to the COBRA
premium amount described above times the number of months remaining in the specified period if the Company determines in its discretion
that continued payment of the COBRA premiums is or may be discriminatory under Section 105(h) of the Code, consistent with Section
409A of the Code, and

(v)              
All unvested Awards and unvested Stock Options held by Executive shall be accelerated and deemed to have vested as of the
date of the Executive’s termination of employment. All Stock Options that have vested (or been deemed pursuant to the immediately
preceding sentence to have vested) as of the date of Executive’s termination of employment shall remain exercisable until
the earlier of the expiry of twelve (12) months following such termination or the termination date applicable under the grant.

The separation benefits
set forth above are conditioned upon Executive executing a Release within the time specified therein, which Release is not revoked
within any time period allowed for revocation under applicable law. The salary and bonus continuation described in Section
10(b)(ii) above will be payable to Executive over time in accordance with the Company’s payroll practices and procedures
beginning on the sixtieth (60th) day following the termination of Executive’s employment with the Company, provided that
the Company, in its sole discretion but in accordance with “Section 409A” (defined below), may begin the payments earlier.
The Prorated Bonus described in Section 10(b)(iii) above shall be paid at the date on which the bonus would have
been paid had Executive continued in employment, and the COBRA payments described in Section 10(b)(iv) above shall
be paid monthly beginning on the date on which the salary continuation commences.

(c)               
Potential Adjustments due to Tax Implications. Notwithstanding anything in this Agreement or any other agreement
between Executive and the Company to the contrary, but subject to this Section 10(c), the Company will effectuate
the acceleration contemplated under Section 10(b) and will make the payments and other acceleration of benefits under
this Agreement and other compensatory arrangements without regard to whether Section 280G of the Code would limit or preclude the
deductibility of such payments or benefits. However, if reducing or eliminating any payment and/or other benefit (including the
vesting of his options or other equity compensation) would increase the “Total After-Tax Payments” (defined below),
then the amounts payable to Executive will be reduced or eliminated as follows (or in such other manner as Executive may specify
at the applicable time if permitted to do so without violation of Internal Revenue Code Sections 280G, 409A and 4999) to the extent
necessary to maximize such Total After-Tax Payments:

(i)                
first, by reducing or eliminating any cash payments or other benefits (other than the vesting of any options or stock) and

(ii)              
second, by reducing or eliminating the vesting of options and stock that occurs as a result of a Corporate Transaction or
other event covered by Section 280G of the Code in reverse order of vesting and with grants whose parachute value is calculated
without regard to Treasury Regulations 280G-1 Q&A 24(c) being reduced prior to those subject to Q&A 24(c).

The Company’s
independent, certified public accounting firm will determine whether and to what extent payments or vesting are required to be
reduced or eliminated in accordance with the foregoing. If there is ultimately determined to be an underpayment of or overpayment
to Executive under this provision, the amount of such underpayment or overpayment will be immediately paid to Executive or refunded
by him, as the case may be, with interest at the applicable federal rate under the Code. The term “Total After Tax
Payments” means the total value of all “parachute payments” (as that term is defined in Section 280G(b)(2)
of the Code) made to Executive or for his benefit (whether made under the Agreement or otherwise), after reduction for all applicable
federal taxes (including, without limitation, the tax described in Section 4999 of the Code). The cost of the accountant shall
be paid by the Company and the accountant shall deliver to the parties its calculations in a form that can be relied upon for filing
of tax returns. The calculations made pursuant to this section shall be made by allocating the full summary compensation table
value (from the latest filed proxy) or an estimate thereof of the Executive’s annual total compensation to the noncompete
set forth in this Agreement.

    -10- 

     

    

11.             
Indemnification.

The Company shall
defend and indemnify Executive regard to his capacities with the Company, its affiliates and its benefit plans to the fullest extent
permitted under the Delaware General Corporate Law (the “DGCL”). The Company shall also maintain a policy
for indemnifying its officers and directors, including but not limited to Executive, for all actions permitted under the DGCL taken
in good faith pursuit of their duties for the Company, including, but not limited to, the obtaining of an appropriate level of
directors and officers liability insurance coverage and including such provisions in the Company’s bylaws or certificate
of incorporation, as applicable and customary. Executive shall be designated as a named insured on such directors and officers
liability insurance policy. Executive’s rights to, and the Company’s obligation to provide, indemnification shall survive
termination of this Agreement.

12.             
Compliance with Code Section 409A.

(a)               
Intent of the Parties. The intent of the Parties is that the payments, compensation and benefits under this Agreement
will be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance
promulgated thereunder (collectively “Section 409A”) and, in this connection, the Agreement shall be
interpreted to be exempt or in compliance with Section 409A. Further, if any benefit or payment payable under this Agreement is
deemed to not comply with Section 409A, the Company and Executive agree to renegotiate in good faith any such benefit or payment
(including, without limitation, as to the timing of any severance payments payable hereunder) so that either (i) Section 409A will
not apply or (ii) compliance with Section 409A will be achieved; provided, however, that any resulting renegotiated terms
shall provide to Executive the after-tax economic equivalent of what otherwise has been provided to Executive pursuant to the terms
of this Agreement, and provided further, that any deferral of payments or other benefits shall be only for such time period as
may be required to comply with Section 409A.

(b)              
Potential Delay of Payment(s) and Adjustments. For the avoidance of doubt, the Parties intend that payments of the
separation benefits set forth in Section 9 and Section 10 above satisfy, to the greatest extent possible,
the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5),
and 1.409A-1(b)(9). If any payment, compensation or other benefit provided to Executive in connection with his separation from
service is determined, in whole or in part, to constitute “nonqualified deferred compensation” within the meaning of
Section 409A and Executive is a “specified employee” within the meaning of Section 409A, no part of such payments shall
be paid before the day that is six (6) months plus one (1) day after the termination date or his earlier death (the “New
Payment Date”). The aggregate of any payments that otherwise would have been paid to Executive during the period
between the termination date and the New Payment Date shall be paid to Executive in a lump sum on such New Payment Date. Thereafter,
any payments that remain outstanding as of the day immediately following the New Payment Date shall be paid without delay over
the time period originally scheduled, in accordance with the terms of this Agreement.

(c)               
Separation from Service. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided
under Section 9 or Section 10 above that constitute “deferred compensation” within the
meaning of Section 409A will not commence in connection with Executive’s termination of employment unless and until Executive
has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)),
unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur additional
tax under Section 409A.

(d)              
Installments; Year of Payment. If any payment, compensation or other benefit required by the Agreement is to be paid
in a series of installment payments, each individual payment in the series shall be considered a separate payment for purposes
of Section 409A. In no event may Executive designate the year of payment of a benefit under this Agreement, except in accordance
with Section 409A.

13.             
Miscellaneous.

(a)               
Governing Law. This Agreement and all questions relating to its validity, interpretation, performance, remediation,
and enforcement (including, without limitation, provisions concerning limitations of actions) shall be governed by and construed
in accordance with the substantive laws of the State of Delaware, notwithstanding any choice-of-law doctrines of that jurisdiction
or any other jurisdiction that ordinarily would or might cause the substantive law of another jurisdiction to apply.

    -11- 

     

    

(b)              
Company Policies. All incentive compensation under this Agreement shall be subject to the terms of any clawback,
recoupment or other policies approved by the Board and applicable to executive officers of the Company.

(c)               
Personal Jurisdiction. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY ACTION OR PROCEEDING RELATING IN ANY
WAY TO THIS AGREEMENT MAY ONLY BE BROUGHT AND ENFORCED IN THE STATE OR FEDERAL COURTS LOCATED IN UNION COUNTY, NEW JERSEY, TO THE
EXTENT SUBJECT MATTER JURISDICTION EXISTS THEREFORE. THE PARTIES IRREVOCABLY SUBMIT TO THE JURISDICTION OF SUCH COURTS IN RESPECT
OF ANY SUCH ACTION OR PROCEEDING. THE PARTIES IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION
THAT THEY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH ACTION OR PROCEEDING IN SUCH COURTS, AS WELL AS ANY CLAIM
THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN ANY INCONVENIENT FORUM.

(d)              
Service of Process. THE PARTIES FURTHER IRREVOCABLY CONSENT TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED
COURTS IN THE MANNER AND TO THE ADDRESS SPECIFIED IN SECTION 13(i) OF THIS AGREEMENT.

(e)               
Waiver of Jury Trial. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN
ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE ACTIONS OF ANY PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF. EACH OF THE PARTIES HERETO
FURTHER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE
MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS
TO THIS AGREEMENT. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

(f)               
Assignment. This Agreement, and Executive’s rights and obligations hereunder, may not be assigned by Executive.
The Company may assign its rights, together with its obligations, hereunder only in connection with any sale, transfer or other
disposition of all or substantially all of its business or assets and to an assignee who assumes such obligations by law or in
writing. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto, and their
respective heirs, legal representatives, successors and assigns.

(g)               
Amendment. This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written
agreement duly executed by the Parties.

(h)              
Waiver. The failure of either Party to insist upon the strict performance of any of the terms, conditions and provisions
of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions
and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either
Party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such Party. Unless the written
waiver instrument expressly provides otherwise, no waiver by a Party of any right or remedy or breach by the other Party in any
particular instance shall be construed to apply to any right, remedy or breach arising out of or related to a subsequent instance.

(i)                
Notices. All notices, demands or other communications desired or required to be given by a Party to the other Party
shall be in writing and shall be deemed effectively given upon (i) personal delivery to the Party to be notified, (ii) upon confirmation
of receipt of fax or other electronic transmission, (iii) one business day after deposit with a reputable overnight courier, prepaid
for priority overnight delivery, or (iv) five days after deposit with the United States Postal Service, postage prepaid, certified
mail, return receipt requested, in each case to the Party to be notified at the Company’s principal executive officers in
the case of the Company and at the latest address of the Executive on the books of the Company in the case of the Executive;
or to such other addresses and to the attention of such other individuals as either Party shall have designated to the other by
notice given in the foregoing manner.

    -12- 

     

    

(j)                
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the
subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral between the Parties,
relating to the subject matter hereof.

(k)              
Affiliate and Control Defined. As used in this Agreement, the term “affiliate” of a specified
Person shall mean and include any Person controlling, controlled by or under common control with the specified Person. A Person
shall be deemed to “control” another Person if such first Person possesses directly or indirectly the
power to direct, or cause the direction of, the management and policies of the second Person, whether through the ownership of
voting securities, by contract or otherwise.

(l)                
Captions, Headings and Cross-References. The section headings contained herein are for reference purposes and convenience
only and shall not in any way affect the meaning or interpretation of this Agreement. Except as expressly set forth otherwise,
all cross-references to sections refer to sections of this Agreement.

(m)            
Severability. In addition to, and not in conflict with, the provisions of Sections 6(b) and 6(f), the
Parties agree that each and every provision of this Agreement shall be deemed valid, legal and enforceable in all jurisdictions
to the fullest extent possible. Any provision of this Agreement that is determined to be invalid, illegal or unenforceable in any
jurisdiction shall, as to that jurisdiction, be adjusted and reformed rather than voided, if possible, in order to achieve the
intent of the Parties. Any provision of this Agreement that is determined to be invalid, illegal or unenforceable in any jurisdiction
which cannot be adjusted and reformed shall for the purposes of that jurisdiction, be voided. Any adjustment, reformation or voidance
of any provisions of this Agreement shall only be effective in the jurisdiction requiring such adjustment or voidance, without
affecting in any way the remaining provisions of this Agreement in such jurisdiction or adjusting, reforming, voiding or rendering
that provision or any other provision of this Agreement invalid, illegal or unenforceable in any other jurisdiction.

(n)              
Counterpart Execution. This Agreement may be executed in one or more counterparts each of which shall be an original
document and all of which together shall constitute one and the same instrument. The Parties acknowledge that this Agreement may
be executed and delivered by means of electronic signatures and that use and acceptance of electronic signatures to bind the Parties
represents the voluntary agreement and intention of the Parties to conduct this transaction by electronic means. The Parties agree
that execution and delivery by electronic means will have the same legal effect as if signatures had been manually written on this
Agreement. This Agreement will be deemed lawfully executed by the Parties by such action for purposes of any statute or rule of
law that requires this Agreement to be executed by the Parties to make the mutual promises, agreements and obligations of the Parties
set forth herein legally enforceable. Facsimile and .pdf exchanges of signatures will have the same legal force and effect as the
exchange of original signatures. THE PARTIES HEREBY WAIVE ANY RIGHT TO RAISE ANY DEFENSE OR WAIVER BASED UPON EXECUTION OF THIS
AGREEMENT BY MEANS OF ELECTRONIC SIGNATURES IN ANY PROCEEDING ARISING UNDER OR RELATING TO THIS AGREEMENT. The Parties agree that
the legal effect, validity and enforceability of this Agreement will not be impaired solely because of its execution in electronic
form or that an electronic record was used in its formation. The Parties acknowledge that they are capable of retaining electronic
records of this transaction.

IN WITNESS WHEREOF,
the Parties hereto have executed this Employment Agreement as of the date set forth above.

Signature page follows.

    -13- 

     

    

 

	CORMEDIX	 	EXECUTIVE
	 	 	 
	/s/ Khoso Baluch	 	/s/ John L. Armstrong
	Date: April 17, 2020	 	John L. Armstrong
	 	 	 
	 	 	Date: April 17, 2020

    -14- 

     

    

 

EXHIBIT A

PRIOR INVENTIONS

    -A-1- 

     

    

 

EXHIBIT B

RELEASE

 

Separation
Agreement and Release

 

This Separation Agreement and Release (the “Agreement”)
sets forth the terms of your separation from employment with CorMedix Inc. (the "Company"). If you understand and agree
with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document
representing the entire agreement between you and the Company regarding the subjects it covers. We will refer to this document
as the "Agreement."

Termination Date. Your last day of work with the Company
will be XXX.

Consideration. The Company will pay you [DESCRIBE
SEVERANCE PAY AND PAYMENT DATES], if you sign and do not revoke this Agreement. The severance pay is provided pursuant to the terms
of the Employment Agreement dated April 17, 2020 between you and the Company (the “Employment Agreement”).

Release of Claims. In exchange for the payment(s)
described in the Consideration clause, you hereby waive all claims available under federal, state or local law against the Company,
its parent, partners and affiliates, and its and their respective directors, officers, employees, agents, insurers and reinsurers,
and employee benefit plans (and the trustees, administrators, fiduciaries, insurers and reinsurers of such plans) past, present,
and future, their heirs, executors, administrators, representatives, successors and assigns arising out of your employment with
the Company or the termination of that employment, including but not limited to all claims arising under the Americans with Disabilities
Act, the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Equal Pay Act, the Genetic Information Non-discrimination
Act, the Family and Medical Leave Act, Section 1981 of U.S.C, Title VII of the Civil Rights Act, and you also hereby waive your
rights under the following statutes to the fullest extent permissible under applicable state and local laws including, but not
limited to the New Jersey Law Against Discrimination, New Jersey Equal Pay Act, New Jersey Civil Rights Law, New Jersey Security
and Financial Empowerment Act, New Jersey Conscientious Employee Protection Act, New Jersey Family Leave Act, New Jersey Wage and
Hour Law, New Jersey WARN Laws, retaliation provisions of New Jersey Workers' Compensation Law, as well as wrongful termination
claims, breach of contract claims, discrimination claims, harassment claims, retaliation claims, whistleblower claims (to the fullest
extent they may be released under applicable law), defamation or other tort claims, and claims for attorneys’ fees and costs.
You are not waiving your right to vested benefits under the written terms of the Company 401(k) Plan, claims for unemployment or
workers’ compensation benefits, any medical claim or any judgment or monetary awards or settlements that may arise related
to medical benefits under the group health plan sponsored by the Company, claims arising after the date on which you sign this
Agreement, claims that are not otherwise waivable under applicable law, or claims to indemnification under Section 11 of the Employment
Agreement. You acknowledge that you have not made any claims or allegations related to sexual harassment or sexual abuse and none
of the payments set forth in this Agreement are related to sexual harassment or sexual abuse.

Medicare Disclaimer. You represent that you are not
a Medicare Beneficiary as of the time you enter into this Agreement.

Limit on Disclosures. You shall not disclose or cause
to be disclosed the terms of this Agreement to any person (other than your spouse or domestic/civil union partner, attorney and
tax advisor), except pursuant to a lawful subpoena, as set forth in the Reports to Government Entities clause below, or as otherwise
permitted by law. This provision is not intended to restrict your legal right to discuss the terms and conditions of your employment.

Restrictive Covenants. You agree to comply with the
confidentiality, inventions, non-competition, non-solicitation and non-disparagement provisions of the Employment Agreement according
to their terms.

Reports to Government Entities. Nothing in this Agreement,
including the Limit on Disclosures or Release of Claims clauses, restricts or prohibits you from initiating communications directly
with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible
violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory
authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor,
the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency
Inspector General (collectively, the "Regulators"), or from making other disclosures that are protected under the whistleblower
provisions of state or federal law or regulation. However, to the maximum extent permitted by law, you are waiving your right
to receive any individual monetary relief from the Company or any others covered by the Release of Claims resulting from such
claims or conduct, regardless of whether you or another party has filed them, and in the event you obtain such monetary relief
the Company will be entitled to an offset for the payments made pursuant to this Agreement. This Agreement does not limit your
right to receive an award from any Regulator that provides awards for providing information relating to a potential violation
of law. You do not need the prior authorization of the Company to engage in conduct protected by this paragraph, and you do not
need to notify the Company that you have engaged in such conduct.

    -B-1- 

     

    

Please take notice that federal law provides criminal and
civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their
attorney, a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. §§
1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with
a lawsuit for retaliation for reporting a suspected violation of the law.

Non-Admission of Liability.  Nothing in this Agreement
is an admission of any wrongdoing, liability or unlawful activity by you or by the Company.

No Other Amounts Due. You acknowledge that the Company
has paid you all wages, salaries, bonuses, benefits and other amounts earned and accrued, less applicable deductions, and that
the Company has no obligation to pay "any additional amounts other than the payments described in the Consideration Clause
of this Agreement.

Addendum to General Release for Age Claims. In addition
to all other claims released for the payment(s) described in the Consideration clause, you hereby waive all claims available against
the Company and the directors, officers, employees, employee benefit plans and agents of the Company arising out of your employment
with the Company or the termination of that employment under the Age Discrimination in Employment Act and the Older Workers Benefit
Protection Act.

Acknowledgement of Voluntariness and Time to Review. 
You acknowledge that:

		·	you read this Agreement and you understand it;

		·	you are signing this Agreement voluntarily in order to release your claims against the Company in exchange for payment that
is greater than you would otherwise have received;

		·	you are signing this Agreement after the date of your separation from the Company and you were offered at least 21 days to
consider your choice to sign this Agreement;

		·	the Company advises you to consult with an attorney;

		·	you know that you can revoke this Agreement within 7 days of signing it and that the Agreement does not become effective until
that 7-day period has passed. To revoke, contact xxx; and

		·	you agree that changes to this Agreement before its execution, whether material or immaterial, do not restart your time to
review the Agreement.

Duty of Cooperation. You agree to cooperate fully
and in a timely manner with the Company and its counsel with respect to any matter (including any litigation, investigation or
governmental proceeding) which relates to your employment with the Company. This cooperation may include appearing from time-to-time
for conferences and interviews, and providing the officers of the Company and its counsel with the full benefit of your knowledge
with respect to any such matter. Subject to the Company's prior approval, the Company will reimburse you for reasonable out-of-pocket
costs and expenses such as travel expenses, and will endeavor to set meeting times that are mutually agreeable.

Governing Law. This Agreement shall be governed by
the laws of New Jersey without reference to that jurisdiction's choice of law rules.

Return of Records and Equipment. You agree that you
have returned all Company property, including but not limited to keys, ID card, cell phone, PDA, and Company documents and information
(either hard copy or electronic) other than records related solely to your own compensation or benefits.

Severability. In the event a court, arbitrator or
other entity with jurisdiction determines that any portion of this Agreement (other than the general release clause) is invalid
or unenforceable, the remaining portions of the Agreement shall remain in full force and effect.

[Signature Page Follows]

    -B-2- 

     

    

The Company hereby advises you to consult with an attorney
prior to signing this Agreement. You acknowledge that you have had a reasonable amount of time to consider the terms of this Agreement
and you sign it with the intent to be legally bound.

 

 

	CorMedix Inc.	 	 
	 	 	 
		Date:    	 
	 	 	 
	 	 	 
	Employee:

	 	 
	 	 	 
	 	Date:    	 

[TO BE SIGNED AFTER
TERMINATION OF EMPLOYMENT]

    -B-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]